GOSS at a glance
Gossamer Bio, Inc. (GOSS, SEC CIK 1728117) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Gossamer Bio, Inc. (GOSS) reported revenue of $48.5 million (down 57.7% from FY2024) and a net loss of $170.4 million. Diluted EPS was -$0.75.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Gossamer Bio, Inc. (GOSS) shares worth $16.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $48.5M
- −57.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $16.7M · +0 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $9.2M, down $2.3M from $11.5M YoY
- Net income $16.9M vs net loss $38.3M YoY, driven by $43.9M debt-extinguishment gain
- Seralutinib largest R&D program at $25.9M vs $41.6M YoY
- Cash, equivalents and marketable securities $57.0M at June 30, 2026
- NDA submission planned for September 2026, with potential FDA decision in third quarter 2027
Risk Factors
- New debt risk triggered by June 2026 Exchange Offer: $65.174M 2030 Notes become due March 2, 2027 if 2027 Notes exceed $4.0M
- Regulatory risk: FDA may reject or require additional trials for seralutinib after PROSERA failed its primary endpoint
- Operational risk: July 2026 termination of Chiesi collaboration returned worldwide seralutinib rights but added milestone and royalty obligations
- Nasdaq compliance risk: bid price below $1.00 for 30 consecutive business days, with compliance deadline October 5, 2026
- Financial dilution risk: Exchange Offer issued 254,150,441 shares and 169,191,727 warrants, with further issuances possible
AI summary of the GOSS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Nasdaq minimum bid-price deficiency cured; continued listing on Nasdaq Global Select Market preserved
- Compliance followed 1-for-80 reverse stock split effective September 10, 2026
Item 8.01: Other Events
- First NDA submitted for seralutinib in pulmonary arterial hypertension, advancing Gossamer’s lead program toward potential commercialization
- Filing supported by Phase 3 PROSERA, Phase 2 TORREY, and supportive analyses
Item 1.01: Entry into a Material Definitive Agreement
- Board appointment of Mr. Ciongoli announced September 16, 2026
- Leadership addition may influence governance and strategic oversight
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Gregory A. Ciongoli appointed Class III director through 2027 annual meeting and Audit Committee member
- Nasdaq-independent director with investment background at Baupost Group and Adiumentum Capital Management
Item EX-99.1: Item EX-99.1
- Greg Ciongoli appointed director effective September 16, 2026, adding public and private investment expertise
- Ciongoli joins the Audit Committee, strengthening financial oversight during seralutinib’s late-stage development
AI summaries of GOSS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GOSS
Don't miss the next GOSS filing
- Alerts as it files. A push when GOSS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GOSS, by share count.
- Ask anything. An AI agent that reads every GOSS filing and answers with sources.
GOSS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cox Russell J. | A | Sep 23, 2026 | 10,000 | - |
| Daniel Thomas O | A | Sep 23, 2026 | 10,000 | - |
| Drynan Skye | A | Sep 23, 2026 | 10,000 | - |
| Milligan Sandra | A | Sep 23, 2026 | 10,000 | - |
| Ciongoli Gregory Austin | A | Sep 23, 2026 | 30,000 | - |
| Quisel John D | A | Sep 23, 2026 | 10,000 | - |
| Nathan Steven D | A | Sep 23, 2026 | 10,000 | - |
| Peterson Caryn | A | Aug 24, 2026 | 5,800,051 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $114.7M | $48.5M |
| Operating Income | - | -$59.9M | -$170.7M |
| Net Income | - | -$56.5M | -$170.4M |
| Op. Margin | - | -52.2% | -352.2% |
| Net Margin | - | -49.3% | -351.5% |
| Balance Sheet | |||
| Total Assets | - | $315.3M | $172.2M |
| Equity | $62.8M | $29.5M | -$122.8M |
| ROE | - | -191.7% | 138.8% |
| Per Share | |||
| EPS | $-1.18 | $-0.25 | $-0.75 |
| Cash Flow | |||
| Operating CF | -$159.2M | -$3.5M | -$171.3M |
| CapEx | $0 | $0 | $79K |
Source: XBRL data in Gossamer Bio, Inc. (GOSS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GOSS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $16.7M |
| Q1 2026 | 23 | $18.7M |
| Q4 2025 | 24 | $192.2M |
| Q3 2025 | 23 | $139.4M |
| Q2 2025 | 24 | $53.3M |
| Q1 2025 | 17 | $29.2M |
| Q4 2024 | 11 | $23.3M |
| Q3 2024 | 10 | $7.8M |
- D.E. Shaw & Co+40.57M (+10418%)
- Renaissance Technologies LLC+10.41M (+855%)
- AQR Capital Management+5.50M (+54%)
- Two Sigma Investments+2.65M (+55%)
- Millennium Management+2.22M (+1182%)
- BlackRock−9.16M (-54%)
- State Street Corp−3.27M (-75%)
- Bank of America Corp−2.78M (-87%)
- Vanguard Portfolio Management LLC−1.62M (-75%)
- Northern Trust−950.5K (-67%)
- StoneX Group Inc.+27.6K
- Citizens Financial Group+13.5K
- T. Rowe Price Group−132.0K
- Principal Financial Group−17.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 155 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GOSS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GOSS SEC filings: frequently asked questions
Which institutions hold GOSS stock?
As of June 30, 2026, the largest Gossamer Bio, Inc. (GOSS) holders among the 13F filers tracked by SignalX were D.E. Shaw & Co ($6.7 million), AQR Capital Management ($2.6 million), Renaissance Technologies LLC ($1.9 million), Vanguard Capital Management LLC ($1.6 million), BlackRock ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GOSS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Gossamer Bio, Inc. (GOSS) reported revenue of $48.5 million (down 57.7% from FY2024) and a net loss of $170.4 million. Diluted EPS was -$0.75. The figures come from the XBRL data in the 10-K.
What did GOSS report in its latest 8-K?
Gossamer Bio, Inc. (GOSS) filed an 8-K on September 28, 2026 reporting Item 8.01 (Other Events). Nasdaq minimum bid-price deficiency cured; continued listing on Nasdaq Global Select Market preserved.
What are the latest GOSS SEC filings?
Gossamer Bio, Inc. (GOSS) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 25, 2026.
What is GOSS's SEC CIK number?
Gossamer Bio, Inc. (GOSS)'s SEC Central Index Key (CIK) is 1728117. EDGAR lists every GOSS filing under that number.
Ask anything about GOSS
The research agent reads GOSS's filings, financials, insider trades and 13F holders, then answers with sources.